重庆智飞生物制品股份有限公司 2024 年度独立董事述职报告 行独立客观判断的关系，不存在影响独立董事独立性的情况，符合《上市公司独 立董事管理办法》《深圳证券交易所上市公司自律监管指引第 2 号——创业板上 市公司规范运作》等法律法规、规范性文件及《公司章程》《独立董事工作制度》 中关于独立董事独立性的相关要求。 （章新蓉） 各位股东及股东代表： 作为重庆智飞生物制品股份有限公司（以下简称"公司"）第六届董事会独立 董事，本人严格按照《中华人民共和国公司法》《中华人民共和国证券法》《上 市公司独立董事管理办法》《深圳证券交易所创业板股票上市规则》《深圳证券 交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》等法律法规、 规范性文件和《公司章程》的要求，忠实、勤勉、尽责地履行职责，按时出席公 司相关会议，认真审议各项议案并审慎决策，充分发挥独立董事的独立性、专业 性作用，维护公司和股东尤其是中小股东的合法权益。现将本人 2024 年度的履 职情况汇报如下： 一、个人基本情况 （一）个人履历信息 本人章新蓉，1959 年 11 月出生，大学学历，中国国籍，无境外居留权。重 庆市审计学会咨询专家，中 ...

重庆智飞生物制品股份有限公司 关联交易决策制度 重庆智飞生物制品股份有限公司 关联交易决策制度 第一章 总则 第一条 为规范重庆智飞生物制品股份有限公司（以下简称"公司"）的关 联交易，保护公司、股东和债权人的合法权益，保证公司关联交易决策行为的公 允性，根据《中华人民共和国公司法》《中华人民共和国证券法》《深圳证券交易 所创业板股票上市规则》等法律、行政法规、规范性文件、深圳证券交易所的相 关规定和《重庆智飞生物制品股份有限公司章程》（以下简称"《公司章程》"）， 结合公司实际情况，制定本制度。 第二条 在本制度中，关联交易是指公司或其控股子公司与公司关联人之间 发生的转移资源或义务的事项，包括： （一）交易事项： 5、租入或者租出资产； 6、签订管理方面的合同（含委托经营、受托经营等）； 1、购买或者出售资产； 2、对外投资（含委托理财、对子公司投资等，设立或者增资全资子公司除 外）； 3、提供财务资助（含委托贷款）； 4、提供担保（指公司为他人提供的担保，含对控股子公司的担保）； 7、赠与或者受赠资产； 重庆智飞生物制品股份有限公司 关联交易决策制度 （二）购买原材料、燃料、动力； （三）销售产品、商品 ...

重庆智飞生物制品股份有限公司 独立董事工作制度 重庆智飞生物制品股份有限公司 独立董事工作制度 第一章 总则 第一条 为进一步完善重庆智飞生物制品股份有限公司（以下简称"公司"） 的法人治理结构，改善董事会结构，强化对内部董事及经理层的约束和监督机制， 保护中小股东及债权人的利益，促进公司的规范运作，根据《中华人民共和国公 司法》《上市公司独立董事管理办法》《深圳证券交易所创业板股票上市规则》 《深圳证券交易所上市公司自律监管指引第2号——创业板上市公司规范运作》等 法律、行政法规、规范性文件、深圳证券交易所的相关规定以及《重庆智飞生物制 品股份有限公司章程》（以下简称"《公司章程》"）的有关规定，结合本公司实 际情况，制定本制度。 第二条 独立董事是指不在公司担任除独立董事外的其他职务，并与公司及 公司主要股东、实际控制人不存在直接或间接利害关系，或者其他可能妨碍其进 行独立客观判断关系的董事。独立董事应当独立履行职责，不受公司及其主要股 东、实际控制人等单位或者个人的影响。 第三条 独立董事对公司及全体股东负有忠实与勤勉义务。独立董事应当认 真履行职责，在董事会中发挥参与决策、监督制衡、专业咨询作用，维护 ...

智通财经4月21日电，智飞生物(300122.SZ)发布2025年第一季度报告，营业收入为23.74亿元，同比下降 79.16%，归属于上市公司股东的净亏损3.05亿元，同比盈转亏。主要原因是市场推广工作未达预期，销 售收入减少。 智飞生物：一季度净亏损3.05亿元 ...

Financial Performance - The company's revenue for Q1 2025 was ¥2,374,498,616.11, a decrease of 79.16% compared to ¥11,395,682,504.71 in the same period last year[3] - The net profit attributable to shareholders was a loss of ¥305,140,593.28, representing a decline of 120.93% from a profit of ¥1,457,744,248.17 in the previous year[3] - Total operating revenue for the current period is ¥2,374,498,616.11, a significant decrease from ¥11,395,682,504.71 in the previous period, representing a decline of approximately 79.1%[18] - The net profit for the current period is a loss of ¥305,140,593.28, compared to a net profit of ¥1,457,744,248.17 in the previous period, indicating a decline of approximately 120.9%[19] Cash Flow and Liquidity - The net cash flow from operating activities was ¥304,155,089.77, a significant improvement of 107.12% compared to a negative cash flow of ¥4,273,676,599.75 in the same period last year[3] - The cash flow from operating activities generated a net cash inflow of ¥304,155,089.77, a recovery from a net outflow of ¥4,273,676,599.75 in the previous period[21] - Cash and cash equivalents at the end of the period increased to ¥3,066,659,017.21 from ¥2,970,554,147.12, reflecting a net increase of ¥367,802,615.23[22] - The company reported a significant increase in cash inflow from financing activities, totaling ¥5,944,474,956.72, compared to ¥4,097,486,152.00 in the previous period, an increase of approximately 45.0%[22] Assets and Liabilities - The total assets at the end of the reporting period were ¥48,340,319,843.45, down 3.14% from ¥49,909,613,835.40 at the end of the previous year[3] - As of March 31, 2025, the company's total assets amounted to CNY 48.34 billion, a decrease from CNY 49.91 billion at the beginning of the period, reflecting a decline of approximately 3.13%[14] - The company's total liabilities decreased from CNY 19.08 billion to CNY 17.81 billion, a reduction of about 6.69%[16] - The total equity attributable to the parent company decreased from CNY 30.83 billion to CNY 30.53 billion, a decline of approximately 0.97%[16] Expenses - The company reported a significant increase in financial expenses, which rose to ¥66,268,710.74, an increase of 1011.22% compared to ¥5,963,609.84 in the previous year[8] - Total operating costs increased to ¥2,434,178,574.47 from ¥9,323,352,619.26, marking an increase of about 26.8%[18] - Research and development expenses for the current period were ¥227,359,676.59, slightly down from ¥234,083,332.08 in the previous period, a decrease of about 2.9%[19] - The company experienced a substantial increase in sales expenses, which amounted to ¥429,766,771.06, compared to ¥495,132,349.15 in the previous period, a decrease of about 13.2%[18] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 126,045, with the largest shareholder holding 48.44% of the shares[10] Strategic Moves - The company acquired a 51% stake in Chongqing Chengan Biopharmaceutical Co., Ltd. through a cash capital increase, indicating a strategic move towards market expansion[13] - The company is actively promoting the asset integration of Chongqing Chengan, which is expected to enhance operational efficiency and market presence[13] Other Information - The company has not yet audited the first quarter report, indicating that the financial results are preliminary and subject to change[23]

Financial Performance - In 2024, the company faced significant challenges due to geopolitical complexities and a sluggish global economy, leading to a decline in revenue and net profit since Q2 2024[4]. - The company reported a substantial decrease in multiple core financial indicators, aligning with the overall downward trend in the vaccine industry[11]. - The company's operating revenue for 2024 was ¥26.07 billion, a decrease of 50.74% compared to ¥52.92 billion in 2023[5]. - The net profit attributable to shareholders for 2024 was ¥2.02 billion, down 74.99% from ¥8.07 billion in 2023[5]. - The net cash flow from operating activities was -¥4.41 billion in 2024, a decline of 149.06% compared to ¥8.99 billion in 2023[5]. - Basic earnings per share for 2024 were ¥0.8427, a decrease of 74.94% from ¥3.3624 in 2023[5]. - The total assets at the end of 2024 were ¥49.91 billion, a slight decrease of 0.64% from ¥50.23 billion at the end of 2023[5]. - The net assets attributable to shareholders at the end of 2024 were ¥30.83 billion, down 2.14% from ¥31.51 billion at the end of 2023[5]. - The company reported a significant decline in quarterly net profit, with the fourth quarter showing a loss of -¥132.14 million[34]. - The company achieved a revenue of 26.07 billion yuan in the reporting period, a decrease of 50.74% compared to the same period last year[78]. - The net profit attributable to shareholders was 2.018 billion yuan, down 74.99% year-on-year[78]. Research and Development - The company has made significant progress in its product pipeline, with nearly ten research projects achieving milestone advancements in 2024, including breakthroughs in pneumonia, meningitis, intestinal, and adult vaccine matrices[5]. - The company is committed to increasing R&D investment and expanding its R&D team to enhance clinical and registration capabilities, aiming for a smoother transition from innovation to commercialization[5]. - The company aims to accelerate the pace of R&D innovation and launch more high-quality products in the future, while also enhancing operational efficiency[7]. - The company has 34 independent R&D projects, with 19 in clinical trials or registration stages, including a 15-valent pneumococcal conjugate vaccine and an ACYW135 meningococcal conjugate vaccine[63]. - The company has built nine major technology R&D platforms, covering various vaccine development paths, ensuring efficient project advancement[59]. - The company has three major R&D and production bases, enhancing its comprehensive R&D strength and product development capabilities[58]. - The company has invested significantly in R&D, focusing on independent innovation while collaborating with leading research institutions, resulting in a rich product pipeline[54]. - The total R&D investment amounted to approximately ¥1.39 billion, representing 5.34% of total revenue, with a significant increase from 2.54% in the previous year[108]. - The company is conducting Phase III clinical trials for multiple vaccines, including the freeze-dried rabies vaccine and the quadrivalent recombinant norovirus vaccine[64]. - The company is in the process of applying for clinical trials for the inactivated varicella-zoster virus vaccine and the monkeypox vaccine[67]. Market Strategy and Expansion - The company plans to optimize its market strategies and strengthen its marketing management system to adapt to market trends and enhance brand influence[12]. - The company recognizes the potential for growth in the vaccine market, driven by increasing public vaccination willingness and the acceleration of innovative vaccines[12]. - Market expansion efforts are underway in Southeast Asia, targeting a 10% market share by 2025[28]. - The company is implementing a new digital marketing strategy, projected to increase online sales by 30%[28]. - The company is focused on optimizing market strategies and resource allocation to enhance market penetration and respond quickly to market changes[82]. - The company is committed to internationalization, enhancing global market expansion and cooperation to improve vaccine accessibility in developing countries[128]. Corporate Governance and Compliance - The company is committed to compliance and transparency, as the industry shifts towards a compliance-driven model, enhancing its core competitiveness[49]. - The company has maintained an "A" rating in information disclosure assessments for nine consecutive years, reflecting its commitment to governance and compliance[140]. - The company emphasizes the importance of regulatory compliance and has a proactive approach to adapting to policy changes in the biopharmaceutical industry[129]. - The company has a structured approach to managing market value, aligning market value with intrinsic value through strategic planning and governance improvements[136]. - The company has implemented measures to reduce bad debt risks, including payment assessments and standardized agreements, in response to increasing accounts receivable due to expanding sales[130]. - The company has a complete and independent financial department, ensuring independent financial decision-making and management[156]. Talent Development and Management - The company emphasizes the importance of talent development, implementing a comprehensive training system to improve employee skills and capabilities[6]. - The company has 1,072 R&D personnel, with 79.82% holding a bachelor's degree or higher[77]. - The management team consists of industry experts with rich experience in disease prevention and control, ensuring effective strategic execution[77]. - The company is focused on expanding its leadership team to drive future growth and innovation[160]. - The company has a diverse management background, with Jiang Rensheng previously serving as general manager and president of Chongqing Zhifei Biological Products Co., Ltd.[161]. Product Development and Innovation - The company has established high-tech research and production bases to continuously innovate in bacterial, viral, and tuberculosis products[50]. - The company has a diverse pipeline of vaccines, including those for rabies, influenza, and COVID-19, positioning it as one of the most comprehensive vaccine developers in the country[62]. - The company is focusing on the development of a quadrivalent hand-foot-mouth disease vaccine, which is currently in preclinical research[67]. - The company is advancing the development of the recombinant herpes zoster vaccine and the EBV vaccine, with the latter still in preclinical research[67]. - The company has obtained a total of 57 authorized patents, including 47 that are currently valid[65]. Financial Management - The company's financial expenses increased by 131.56% to approximately ¥109.34 million, primarily due to higher interest expenses from bank loans[107]. - The company's total operating costs decreased by 51.05% to approximately ¥18.93 billion, with a significant reduction in procurement costs for agency products[101]. - Cash inflow from financing activities increased by 132.19% to ¥14.74 billion, primarily due to an increase in short-term borrowings[110]. - The company has conducted a share repurchase of over 300 million yuan, with all repurchased shares being canceled to reduce registered capital, enhancing shareholder returns[140]. Social Responsibility and Public Engagement - The company maintains a commitment to social benefits over corporate profits, aligning its vision with national development goals[7]. - The company is actively engaged in public relations to manage potential public sentiment risks associated with vaccine hesitancy and increasing social attention[131]. - The company is focused on promoting vaccine value through academic outreach to combat vaccine hesitancy and improve public understanding[131].

证券代码：300122 证券简称：智飞生物 公告编号：2025-22 重庆智飞生物制品股份有限公司 关于续聘公司 2025 年度审计机构的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 重庆智飞生物制品股份有限公司（以下简称"公司"）于 2025 年 4 月 18 日召 开第六届董事会第五次会议、第六届监事会第四次会议，审议通过了《关于续聘 公司 2025 年度审计机构的议案》，同意续聘信永中和会计师事务所（特殊普通合 伙）（以下简称"信永中和"）为公司 2025 年度审计机构，聘期一年，自公司 2024 年年度股东大会审议通过之日起生效。本事项尚需提交公司 2024 年年度股东大 会审议。 本次续聘会计师事务所符合财政部、国务院国资委、证监会印发的《国有企 业、上市公司选聘会计师事务所管理办法》（财会〔2023〕4 号）的规定。现将 具体情况公告如下： 一、拟聘任会计师事务所的基本情况 （一）机构信息 1、基本信息 注册地址：北京市东城区朝阳门北大街 8 号富华大厦 A 座 8 层 首席合伙人：谭小青先生 截止 2024 年 12 月 31 日，信永中 ...

证券代码：300122 证券简称：智飞生物 公告编号：2025-20 本公司及董事会全体成员保证公告内容的真实、准确和完整，不存在虚假 记载、误导性陈述或者重大遗漏。 重庆智飞生物制品股份有限公司（以下简称"公司"）于 2025 年 4 月 18 日召开第六届董事会第五次会议，审议通过了《关于公司 2025 年向银行申请授 信额度的议案》，同意公司向金融机构申请授信额度，具体情况如下： 为保障公司经营目标的顺利实现，结合业务发展的实际需要，公司拟维持原 有银行综合授信额度，向中国进出口银行、中国工商银行股份有限公司、中国农 业银行股份有限公司、中国建设银行股份有限公司、中国银行股份有限公司、招 商银行股份有限公司、中国民生银行股份有限公司、兴业银行股份有限公司、上 海浦东发展银行股份有限公司、中国光大银行股份有限公司、中信银行股份有限 公司、重庆农村商业银行股份有限公司、重庆银行股份有限公司及渣打银行（中 国）有限公司等金融机构申请敞口总额不超过人民币 360 亿元的授信额度。 授信业务包含但不限于银行承兑汇票、流动资金贷款、并购贷款、供应链解 决方案、进岀口贸易融资、保函、远期资金交易等业务品种；用信业务根 ...

重庆智飞生物制品股份有限公司 2024 年度内部控制评价报告 1 重庆智飞生物制品股份有限公司 2024 年度内部控制评价报告 重庆智飞生物制品股份有限公司 2024 年度内部控制评价报告 重庆智飞生物制品股份有限公司全体股东： 为加强和规范企业内部控制，提高企业经营管理水平和风险防范能力，促进 企业可持续发展，根据《企业内部控制基本规范》及其配套指引的规定和其他内 部控制监管要求（以下简称"企业内部控制规范体系"），结合重庆智飞生物制品 股份有限公司（以下简称"公司"）内部控制制度和评价办法，在内部控制日常 监督和专项监督的基础上，公司对 2024 年度内部控制及运行情况进行了全面检 查，对 2024 年 12 月 31 日（内部控制评价报告基准日）的内部控制有效性进行 了评价。 一、重要声明 按照企业内部控制规范体系的规定，建立健全和有效实施内部控制，评价其 有效性，并如实披露内部控制评价报告是公司董事会的责任。监事会对董事会建 立和实施内部控制进行监督。经理层负责组织领导企业内部控制的日常运行。公 司董事会、监事会及董事、监事、高级管理人员保证本报告内容不存在任何虚假 记载、误导性陈述或重大遗漏，并对报 ...